# A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

> **NCT07207395** · PHASE2 · RECRUITING · sponsor: **The Christ Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)

## Interventions

- **DRUG:** JBI-802
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07207395
- **Lead sponsor:** The Christ Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-29
- **Primary completion:** 2027-10
- **Final completion:** 2028-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07207395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07207395, "A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07207395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*